Undisclosed BLIMP1 PROTAC / AstraZeneca - LARVOL DELTA

Development and characterization of a potent and selective BLIMP1 protac as a novel, first-in-class therapy for multiple myeloma (ASH 2025) - "Co-treatment with dexamethasone resulted in amarked increase in cell death across various myeloma cell lines. Our work is the first to identify BLIMP1 as a highly actionable target in myeloma. First-in-class BLIMP1PROTACs demonstrate robust and selective BLIMP1 degradation and anti-myeloma activity asmonotherapy and in combination with anti-myeloma agents. BLIMP-IMiDs provide a dual-targetingstrategy that overcomes combination limitations, showing deep, broad anti-myeloma responses andhighlighting BLIMP1-directed degradation as a promising therapy."

Hematological Malignancies • Lymphoma • Multiple Myeloma • Targeted Protein Degradation • ATF4 • CDKN2B • CRBN • ERN1 • IKZF1 • IKZF3 • MYC • PRDM1 • XBP1